Sangamo BioSciences | SGMO - Ebitda


Sangamo BioSciences reported $-67.97M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amgen USD 3.86B 1.28B Mar/2026
Bayer EUR 2.14B 2.31B Jun/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cipla INR 14.03B 4.48B Jun/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Grifols EUR 482.04M 7.04M Sep/2025
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Omeros USD -47.96M 7.39M Sep/2023
Pfizer USD 6.01B 18M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026